GlycoDisplay Aps was founded 2016 by Professor Henrik Clausen and four cofounders from Copenhagen Center for Glycomics at University of Copenhagen. The team has extensive experience with research in Glycomics, glycoengineering of mammalian cell lines and industry know-how on the development of biologics.

**** NOW OFFERING COVID-19 SUGAR TOOLS FOR VACCINE AND DRUG DEVELOPMENT **** GlycoDisplay develop novel biopharmaceuticals by modifying glycans. We apply targeted cell engineering allowing display of the glycoforms on drug candidates and drug targets.

The Glycodisplay business model focuses on specific drug programs where glyco-optimized leads are identified in close collaboration with pharmaceutical companies. GlycoDisplay delivers expertise within glyco-engineering, and pharma partners add know-how and capabilities within disease area, assays and animal models.